Pernix Therapeutics (NASDAQ:PTX) Stock Price Up 728%

Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) rose 728% during trading on Friday . The stock traded as high as $0.21 and last traded at $0.21. Approximately 0 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 3,039,640 shares. The stock had previously closed at $0.03.

A hedge fund recently raised its stake in Pernix Therapeutics stock. Barclays PLC raised its position in shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) by 120,196.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 69,772 shares of the specialty pharmaceutical company’s stock after purchasing an additional 69,714 shares during the quarter. Barclays PLC owned about 0.48% of Pernix Therapeutics worth $29,000 as of its most recent SEC filing. 20.43% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Pernix Therapeutics (NASDAQ:PTX) Stock Price Up 728%” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/06/14/pernix-therapeutics-nasdaqptx-stock-price-up-728.html.

About Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.

Read More: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.